Cargando…

Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research

Purpose: Essential thrombocythemia, polycythemia vera, and myelofibrosis are rare chronic hematological malignancies known as myeloproliferative neoplasms (MPNs) and are characterized by deregulated myeloid lineage cell production, splenomegaly, and heterogeneous symptom profiles. MPN patients suffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckert, Ryan, Huberty, Jennifer, Gowin, Krisstina, Mesa, Ruben, Marks, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739136/ https://www.ncbi.nlm.nih.gov/pubmed/27458250 http://dx.doi.org/10.1177/1534735416661417

Ejemplares similares

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research
por: Huberty, Jennifer, et al.
Publicado: (2019)

Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study
por: Huberty, Jennifer, et al.
Publicado: (2018)

The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms
por: Gowin, Krisstina, et al.
Publicado: (2020)

Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
por: Win, Hninyee, et al.
Publicado: (2022)

Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials
por: Huberty, Jennifer, et al.
Publicado: (2019)

Associations Between Global Mental Health and Response to an App-Based Meditation Intervention in Myeloproliferative Neoplasm Patients
por: Puzia, Megan E., et al.
Publicado: (2020)

Experiences of Using a Consumer-Based Mobile Meditation App to Improve Fatigue in Myeloproliferative Patients: Qualitative Study
por: Huberty, Jennifer, et al.
Publicado: (2019)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
por: Langlais, Blake T., et al.
Publicado: (2021)

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
por: Christensen, Sarah F., et al.
Publicado: (2021)

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
por: Padrnos, Leslie, et al.
Publicado: (2020)

Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
por: Christensen, Sarah Friis, et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
por: Duncombe, Andrew S., et al.
Publicado: (2020)

Angiogenesis in myeloproliferative neoplasms, new markers and future directions
por: Medinger, Michael, et al.
Publicado: (2014)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
por: Win, Hninyee, et al.
Publicado: (2020)

A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial
por: Huberty, Jennifer, et al.
Publicado: (2020)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy
por: Mann, Shivtaj, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_58aeu5u5jevj9u1n06t7dtv9di